Pelthos Therapeutics (PTHS) EBT Margin (2025 - 2026)

Pelthos Therapeutics (PTHS) posted quarterly EBT Margin of 173.24% for Q4 2025, up 96.95% quarter-over-quarter from 5681.29% in Q3 2025.

Pelthos Therapeutics (PTHS) EBT Margin (2025 - 2026) Analysis & Trends

Pelthos Therapeutics' EBT Margin history runs 1 years deep, the most recent figure standing at 173.24% for Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	35.61%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	35.71%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-528.97%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	18.33%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	13.77%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-2.67%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	12.09%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-25.06%
10	Pelthos Therapeutics	96.56 Mn	72.00 Mn	21.23 Mn	-182.92%

Download Data